- |||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. (Pubmed Central) - Oct 3, 2021 NLRP3 inflammasome, a macromolecular structure sensing damage and releasing pro-inflammatory cytokines, is centrally involved as it releases interleukin (IL)-1β, whose auto-induction feeds an autoinflammatory disease, mostly responsible for recurrences. Colchicine, an inhibitor of NLRP3 inflammasome formation, and IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.
- |||||||||| Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
Preclinical, Review, Journal: Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models. (Pubmed Central) - Sep 5, 2021 For instance, treatments that focus on systemically negating IL-1β (i.e., anakinra, rilonacept, and canakinumab) have been reported to result in an escalated peril of infections. Therefore, given the therapeutic promise of an NLRP3 inhibitor, the concerted escalated venture of the scientific sorority in the advancement of small molecules focusing on direct NLRP3 inflammasome inhibition is quite predictable.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: The IL-1 trap rilonacept resolves and prevents recurrent pericarditis. (Pubmed Central) - Sep 2, 2021 Therefore, given the therapeutic promise of an NLRP3 inhibitor, the concerted escalated venture of the scientific sorority in the advancement of small molecules focusing on direct NLRP3 inflammasome inhibition is quite predictable. No abstract available
- |||||||||| mavrilimumab (KPL-301) / Kiniksa
Review, Journal: Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review. (Pubmed Central) - Aug 20, 2021 Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia. With this review paper, we aim to demonstrate the inhibitory effect of mavrilimumab on cytokine storms in patients with COVID-19 by reviewing published clinical trials and emphasize the importance of extensive future trials.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: New Indication for Rilonacept. (Pubmed Central) - Aug 11, 2021 Rilonacept (Araclyst) has been approved to treat recurrent pericarditis and to reduce the risk of recurrence in adults and children 12 years of age and older. The drug is given subcutaneously.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments. (Pubmed Central) - Aug 5, 2021 Recent studies added evidence to the importance of anti-IL-1 drugs in the treatment of recurrent pericarditis with raised C-reactive protein. In the era of tailored medicine, anti-IL-1 agents may be very useful in the subset of patients with recurrent pericarditis and a clear inflammatory phenotype.
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
[VIRTUAL] Anti-interleukin 1 agents for the treatment of recurrent pericarditis. () - Jul 6, 2021 - Abstract #ESC2021ESC_4478; After discontinuing rilonacept during RW, HRQoL scores worsened at recurrence and improved upon receipt of bail-out rilonacept, similar to pain. In patients with RP, anti-IL-1 agents (anakinra and rilonacept) are efficacious for prevention of recurrences, without severe adverse events.
- |||||||||| mavrilimumab (KPL-301) / Kiniksa
Trial completion, Trial primary completion date: KPL-301 for Subjects With Giant Cell Arteritis (clinicaltrials.gov) - Jul 2, 2021 P2, N=70, Completed, In patients with RP, anti-IL-1 agents (anakinra and rilonacept) are efficacious for prevention of recurrences, without severe adverse events. Active, not recruiting --> Completed | Trial primary completion date: Dec 2020 --> Aug 2020
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Journal: Pericarditis (Pubmed Central) - Jul 1, 2021 Other IL-1 receptor antagonists have shown promising results (canakinumab, rilonacept). Further evaluation in larger prospective clinical trials is needed to confirm the long-term efficacy and safety of anti-IL1."
- |||||||||| Arcalyst (rilonacept) / Regeneron, Kiniksa
Review, Journal: Acute recurrent pericarditis: from pathophysiology towards new treatment strategy. (Pubmed Central) - Jun 30, 2021 Other IL-1 receptor antagonists showed promising results (canakinumab, rilonacept). However, IL-1 receptor antagonists' position in the treatment algorithm of recurrent pericarditis needs further evaluation in larger prospective clinical trials to replicate initial findings as well as to assess safety, cost-effectiveness and long-term efficacy.
- |||||||||| Ilaris (canakinumab) / Novartis
Clinical, Journal: Canakinumab for the treatment of adult-onset Still's disease. (Pubmed Central) - Jun 24, 2021 The choice of treatment is a relevant issue for patients and the national health services. The available data for canakinumab indicate that this drug in AOSD patients is effective and well tolerated.
- |||||||||| Clinical, Review, Journal: Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome. (Pubmed Central) - Jun 11, 2021
Canakinumab, anakinra, etanercept and rilonacept were reported to be well tolerated; however, injection-site reactions were observed frequently with anakinra, rilonacept and etanercept. Data on the use of tocilizumab, infliximab and adalimumab in these conditions were limited; thus, further research is warranted.
- |||||||||| Stelara (ustekinumab) / J&J, mavrilimumab (KPL-301) / Kiniksa, Actemra IV (tocilizumab) / Roche, JW Pharma
Preclinical, Journal: Giant cell arteritis: what is new in the preclinical and early clinical development pipeline? (Pubmed Central) - Jun 10, 2021 However, much remains to be learned about its optimal usage in GCA and a substantial minority of patients do not achieve sustained glucocorticoid-free remission with tocilizumab. Numerous exciting new agents are under investigation to fill this treatment gap in GCA, with the GM-CSF inhibitor mavrilimumab, and IL-12/23 blockade with ustekinumab providing promise through targeting the GCA pathogenic pathway in its proximal portion.
- |||||||||| Journal: Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. (Pubmed Central) - May 22, 2021
Lymphocyte‑targeting agents include rituximab and belimumab, which act against B cells by different mechanisms, and abatacept, which is a T cell costimulation modulator...Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, and upadacitinib) and phosphodiesterase 4 inhibitors (apremilast) form this group...During pregnancy limited data exits, but anti-TNFα, rituximab, and anakinra seem to be safe. Biologic agents are expensive, but biosimilars have raised as a more cost-effective option and an opportunity to treat a greater number of patients.
|